⌕
Supernus · INDV · Nasdaq
Tenet — · insufficient data
Compare
$36.28+2.57%At close
$36.28+0.91 (+2.57%)
At close: Nov 2, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Nov 2, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Supernus (INDV) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● The Motley FoolNov 2, 2026 · 16:43 ET
Why Indivior Pharmaceuticals Stock Topped the Market Today

The peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.…

● GlobeNewsWireOct 29, 2026 · 07:00 ET
Indivior Reports Third Quarter 2026 Financial Results

Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAAP Net Income of $ 16…

● Defense WorldOct 22, 2026 · 02:41 ET
Indivior (INDV) Projected to Announce Earnings on Thursday

Indivior (NASDAQ: INDV - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Indivior to post earnings of $1.06 per share and revenue of $329.…

● GlobeNewsWireOct 19, 2026 · 08:30 ET
Indivior to Report Third Quarter 2026 Financial Results

RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will …

● Defense WorldOct 18, 2026 · 02:15 ET
Indivior PLC (NASDAQ:INDV) Stock Has Average Price Target of $45.17

Shares of Indivior PLC (NASDAQ: INDV - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with…

● Defense WorldSep 25, 2026 · 04:15 ET
Financial Contrast: Sonoma Pharmaceuticals (NASDAQ:SNOA) versus Indivior (NASDAQ:INDV)

Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Indivior (NASDAQ: INDV - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the stre…

● Business WireSep 24, 2026 · 17:40 ET
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals,…

● GlobeNewsWireSep 17, 2026 · 07:00 ET
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend

RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the am…

● Zacks Investment ResearchSep 14, 2026 · 10:30 ET
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.…

● Defense WorldSep 12, 2026 · 03:39 ET
HighTower Advisors LLC Makes New $3.41 Million Investment in Indivior PLC $INDV

HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ: INDV) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 83,088 sha…

● Business WireAug 29, 2026 · 07:27 ET
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Trans…

● Zacks Investment ResearchAug 21, 2026 · 13:40 ET
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.…

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.